Digital PCR analysis of circulating tumor DNA: a biomarker for chondrosarcoma diagnosis, prognostication, and residual disease detection by Gutteridge, A et al.
1Introduction
Conventional central chondrosarcoma (CS) is the most 
common bone sarcoma in adults with an incidence of 
~1/100,000/year. Clinical outcome has not changed in 
30 years and tumor grade (G) is the best prognosticator 
of metastatic disease, and survival, aside from when the 
lesions occur in the phalanges as these have a negligible 
risk of metastasis. Enchondromas and CS GI (classified as 
well differentiated cartilaginous tumors when grouped 
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Abstract
Conventional chondrosarcoma is the most common primary bone tumor in 
adults. Prognosis corresponds with tumor grade but remains variable, especially 
for individuals with grade (G) II disease. There are currently no biomarkers 
available for monitoring or prognostication of chondrosarcoma. Circulating tumor 
DNA (ctDNA) has recently emerged as a promising biomarker for a broad range 
of tumor types. To date, little has been done to study the presence of ctDNA 
and its potential utility in the management of sarcomas, including chondrosar-
coma. In this study, we have assessed ctDNA levels in a cohort of 71 patients, 
32 with sarcoma, including 29 individuals with central chondrosarcoma (CS) 
and 39 with locally aggressive and benign bone and soft tissue tumors, using 
digital PCR. In patients with CS, ctDNA was detected in pretreatment samples 
in 14/29 patients, which showed clear correlation with tumor grade as demon-
strated by the detection of ctDNA in all patients with GIII and dedifferentiated 
disease (n = 6) and in 8/17 patients with GII disease, but never associated with 
GI CS. Notably detection of ctDNA preoperatively in GII disease was associated 
with a poor outcome. A total of 14 patients with CS had ctDNA levels assessed 
at multiple time points and in most patients there was a clear reduction follow-
ing surgical removal. This research lays the foundation for larger studies to assess 
the utility of ctDNA for chondrosarcoma diagnosis, prognostication, early detec-
tion of residual disease and monitoring disease progression.
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together) in a long bone have an excellent prognosis and 
can generally be cured by curettage and local adjuvant 
therapy. In contrast, high- grade disease (combined GII and 
GIII) has a ~53% 5 years survival rate but when assessed 
according to grade the 5 and 10 years survival rate of GII 
is 81% and 64%, and GIII is 43% and 29%, respectively 
[1]. Approximately 10% of cases that recur reveal an increase 
in grade. It is however well recognized that there is sig-
nificant inter- and intra- observer variability when grading 
these tumors [2]. About 10–15% of CS transform into a 
nonconventional variant known as dedifferentiated CS asso-
ciated with a low 5 years survival, ranging from 7% to 
24% [3]. Typically resistant to chemotherapy and radio-
therapy, GII and III disease are treated by en bloc excision 
and a prosthetic implant when required. Patients with 
dedifferentiated CS may be treated with chemotherapy [4].
Patients with CS would benefit from being provided 
with a more accurate prognosis particularly for those 
diagnosed with GII disease. A biomarker that would detect 
residual disease directly postsurgery, and earlier detection 
of disease relapse than is achieved using current imaging 
technologies, would also improve the clinical management 
of these patients. In addition, a blood- based biomarker 
that could be employed in the absence of a CT- guided 
biopsy would reduce the number of invasive tests. 
Development of an assay to detect circulating tumor DNA 
(ctDNA) in patients with CS could address these chal-
lenges as it is now well established that a broad range 
of cancer types release mutant DNA into the blood stream 
[5]: this is being extensively studied in many tumor types 
for the applications listed above [6–9]. To the best of 
our knowledge there have only been two studies that 
have analyzed ctDNA in sarcoma to date: both studies 
assessed high- grade disease including a single patient with 
widespread osteosarcoma [10] and a cohort of 20 patients 
with Ewing sarcoma [11].
Isocitrate dehydrogenase type 1 (IDH1) and IDH2 muta-
tions are present in close to 60% of central cartilaginous 
tumors: the former is present in 50–55% with IDH2 
alterations being detected in ~6% of central lesions [12]. 
The mutations are present ab initio and retained through-
out disease progression including transformation into 
dedifferentiated chondrosarcoma [13]. All reported IDH1 
mutations in CS have been identified in codon 132 and 
comprise five different nucleotide changes (R132H, C, G, 
S, L) [12]. Hence, central conventional CS is well suited 
to ctDNA analysis. The same mutations are also considered 
to be the key driver in the development of Ollier disease 
and Maffucci syndrome, the most common form of 
enchondromatosis, a well characterized mosaic disorder 
[14, 15].
The primary aim of this pilot study is to determine if 
mutant IDH1 DNA can be detected in the plasma of 
patients whose tumors harbor such mutations and whether 
such a test could potentially be useful as a prognostic 
and diagnostic marker in the future.
There are a number of other bone and soft tissue tumors 
which harbor recurrent point mutations including a 
MYOD1 p.L122R mutation in a large percentage of spindle 
cell rhabdomyosarcoma [16, 17], an exceptionally rare, 
and aggressive high- grade tumor. Other examples include 
CTNNB1 in desmoid- type fibromatosis [18], GNAS in 
fibrous dysplasia [19] and intramuscular myxoma [20], 
and H3F3 alterations in giant cell tumor (GCT) of bone 
and chondroblastoma [21, 22]. However, in contrast to 
CS these do not represent high- grade disease. Nevertheless, 
it would be of interest to establish if these alterations 
could be detected in the plasma of affected individuals.
Materials and Methods
Patient recruitment and sample collection
Whole blood, blood plasma, and tissue were banked where 
feasible from patients attending the London Sarcoma 
Service with peripherally sited sarcomas, including CS. 
Samples from 29 patients with IDH1-mutant CS were 
identified for this study (Table S1). Three patients had 
extensive Ollier disease. Pretreatment plasma was also 
tested from patients with spindle cell rhabdomyosarcoma 
(n = 3), giant cell tumor of bone (n = 24), desmoid- type 
fibromatosis (n = 5), fibrous dysplasia (n = 4) and intra-
muscular myxoma (n = 6) (Table S2). Blood plasma from 
12 additional individuals with lipoma was used as normal 
controls. Samples were obtained from the Stanmore 
Musculoskeletal Biobank, a satellite of the UCL/UCLH 
Biobank (HTA License number 12055), which was approved 
by the National Research Ethics Committee (Reference 
15/YH/0311). This specific study was approved by the 
NREC- approved UCL/UCLH Biobank Ethical Review 
Committee (Reference EC17.14).
The tissue diagnoses and grading of tumors were reviewed 
and confirmed independently by three pathologists (AMF, 
RT, FA) blinded to the original diagnostic report. Diagnostic 
criteria were based on the WHO classification [3]. Tumor 
DNA samples from patients with CS whose plasma was 
analyzed were confirmed to have one of the IDH1 R132 
mutations of interest using a combination of a range of 
techniques including capillary sequencing, Sequenom™ 
MassARRAY and digital PCR [12, 14]. Chondrosarcoma 
samples with IDH2 mutations were not included in the study.
In tumor types other than chondrosarcoma, the follow-
ing hotspot mutations were confirmed in the tumor samples 
before assessing the ctDNA: MYOD1 mutation (p.L122R) 
in spindle cell rhabdomyosarcoma, CTNNB1 mutations 
(p.T41A and p.S45F) in desmoid- type fibromatosis [18], 
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GNAS mutations (p.R201H, p.R201C) in fibrous dysplasia 
[19] and intramuscular myxoma [20], and H3F3A altera-
tions (p.G34W) in giant cell tumor of bone [21, 22]. 
Various methods were used to determine the mutation 
status of these samples, including capillary, whole genome, 
exome sequencing, amplicon based targeted next- generation 
sequencing (ion torrent), Sequenom™ MassARRAY, digital 
PCR, and mutation- specific restriction digestion.
Blood plasma was collected following a standard operat-
ing procedure optimized for ctDNA analysis. In brief, 
blood was drawn into 10 mL EDTA tubes and processed 
no more than 4 h after collection by a 10 min centrifu-
gation at 4°C at 272x g, followed by centrifugation of 
the upper plasma layer at 20,000x g for 10 min to remove 
any cellular debris. Plasma was stored at −80°C until DNA 
was extracted.
DNA extraction from blood plasma
DNA from plasma samples was extracted using the 
QIAamp® Circulating Nucleic Acid kit (Qiagen, Hilden, 
Germany) according to the manufacturer’s instructions, 
using an elution volume of 50 μL. Eluent was passed 
twice through the extraction column to increase extraction 
efficiency. DNA was stored at −20°C until required for 
digital PCR analysis.
IDH1 multiplex assay development
Initial assay design was carried out using Beacon Designer 
software (PREMIER Biosoft, CA). Probes were developed 
targeting wild type and all common IDH1 mutations 
(R132C, G, H, L and S) in central CS [12]. The ability 
to detect all five mutations was demonstrated through 
analysis of tumor DNA with known mutations as assessed 
by at least two assays (Sequenom™ MassARRAY, capillary 
sequencing, exome or sequencing). A validated single- 
nucleotide polymorphism at an incidence of 0.0008–0.02% 
(rs148542200) was located in the optimal position for the 
reverse primer: for this reason two reverse primers were 
used to ensure assay compatibility for all patients. A syn-
thetic long oligonucleotide was used as a template to 
demonstrate that both alleles amplify equally efficiently 
with this PCR primer strategy (data not shown; Sigma- 
Aldrich, MO).
Assays targeting hotspots in MYOD1 (p.L122R), H3F3A 
(p.G34W), CTNNB1 (p.T41A, p.S45F) and GNAS1 
(p.R201C, p.R201H) were also developed (Data S1).
Digital PCR
DNA was analyzed on the QX200 Droplet Digital PCR 
System (Bio- Rad, CA). 20 μL reactions consisting of up 
to 9 μL DNA, 10 μL Supermix for Probes (no dUTP; 
Bio- Rad), assay oligos (Tables S3–S5) and nuclease- free 
water were partitioned into approximately 23,000 ~0.85 nL 
volume droplets and underwent 40 cycles of PCR (Table 
S6). Early experiments conducted as part of an optimiza-
tion procedure were carried out: details are described in 
the supplementary material.
Between 0.16 and 6.27 mL of plasma were analyzed 
for each time point. If high ctDNA levels were detected 
in the first aliquots analyzed (≥5 mutant droplets) the 
remaining plasma was saved. All available plasma was 
analyzed if insufficient molecules were detected.
At the data acquisition stage, droplets were read with 
the FAM/VIC channel and RED (Rare Event Detection) 
setting provided by the QuantaSoft 1.7.4 software package 
(Bio- Rad, CA). Droplets were manually called as mutant 
only, wild type only, double- positive or template negative 
by the same technician throughout the study.
Positive controls and no- template controls were included 
in every run. For the multiplex analyses, a single- reaction 
positive control was created for all five mutations by 
pooling PCR amplicons from five tumor DNA samples. 
The mutation in each tumor was verified in a singleplex 
experiment. This positive control acted as an intra- plate 
reference for calling droplets, as well as an inter- plate 
control for intermediate precision of the assay. No- template 
control results are listed in Table S7.
A commercially available pooled sample of human pla-
cental DNA was used as a mutation negative control 
(BioLine, London, UK) for bulk analysis of the assay 
background error rate. ~0.95 μg of human genomic DNA 
was loaded across 19 reactions for total analysis of approxi-
mately 289,000 haploid copies. In total 16 mutant droplets 
were detected (2 “mutant only”, and 14 double 
positive).
Based on this background error rate (1 mutant droplet 
per ~18,000 wild type droplets), and the average number 
of molecules we assessed per time point (n = 1,493), 
blood samples were deemed to be ctDNA mutant- positive 
if they had a minimum of 2 “mutant only” droplets. 
Samples with just a single mutant droplet were classified 
as equivocal and treated as negative for analysis. Analysis 
of cell- free DNA from 12 donors with lipoma did not 
detect a single IDH1 mutant molecule demonstrating the 
specificity of this assay. Mutant levels are reported in 
terms of mutant copies per mL of blood plasma analyzed. 
In order to calculate this, the variable dead volume of 
the BioRad platform has been factored in.
Data analysis
Concentration values and raw droplet counts as produced 
by QuantaSoft were taken forward for analysis. Individual 
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reactions with 2D plots indicative of typical assay failure 
or with mutant- only droplets less than or equal to the 
number in the no template control combined were excluded 
from analysis (Fig. S1).
Results
Of the 29 patients with IDH1- mutant CS selected for this 
study, 15 patients had only preoperative samples analyzed 
whereas a variable number of pre- and post- operative 
serial blood samples was available throughout the course 
of treatment from the remaining 14 patients. In total 73 
separate time points were analyzed. Preoperative ctDNA 
levels were detected in 14 patients including all patients 
with GIII (n = 2) and dedifferentiated (n = 4) CS, 8/17 
patients with CS GII, but 0/6 patients with CS GI (Fig. 1).
Correlation of the ctDNA data with clinical records 
revealed that detection of preoperative ctDNA in 8/17 
patients with GII CS was associated with a poor prognosis 
compared to those in whom ctDNA was not detected: 
3/8 ctDNA- positive patients with GII disease had died by 
the end of the study (CS06, CS15, CS21) (P- value = 0.0448 
Log- rank (Mantel- Cox test) (Fig. 2A). A fourth patient 
(CS09) suffered a local recurrence, and a fifth patient 
(CS24) presented with metastatic disease 2 years following 
the primary surgery, which was subsequently excised: this 
patient has lung metastases. In contrast 8/9 of those in 
whom preoperative ctDNA was not detected were disease- 
free aside from one patient whose tumor recurred as a 
small lesion in the phalanx (CS03). Larger tumor size 
(largest tumor dimension) was also associated with detec-
tion of ctDNA in individuals with GII tumors and above 
(P- value = 0.001683, Welch Two Sample t- test) (Fig. 2B).
Of the 14 patients whose plasma was analyzed both 
pre- and post- surgery, ctDNA was detected presurgery in 
9 (Fig. 3 and Table S1). Mutant IDH1 ctDNA levels from 
7 of these 9 patients was clearly reduced following surgery 
(average time when first sampled 92 days) (CS09- 192 days, 
CS10- 130 days, CS21- 3 days, CS24- 107 days, CS12- 
139 days, CS13- 162 days & CS27- 2 days) although in 
patient (CS27), with a dedifferentiated CS, the ctDNA 
subsequently had risen significantly when measured at day 
118 reflecting disease progression (local recurrence and 
metastatic disease) (Fig. 3). Notably there were 5 patients 
in whom ctDNA was detectable in their first postsurgery 
sample. In patient (CS14) with extensive Ollier disease 
Figure 1. Number of mutant molecules per mL/plasma pretreatment. Patients were sorted by grade and ctDNA level. Three patients (CS01, CS04 & 
CS14) had multiple pretreatment timepoints. The mean of these values was taken, with 1 standard deviation displayed as error bars. Equivocal results, 
where only 1 mutant droplet was detected are denoted with a*. Patients with Ollier disease are identified with a#. CS14 had 3 separate tumors 
analyzed and has been grouped according to the highest grade.
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the ctDNA level rose postoperatively and remained high 
for 236 days in the absence of clinically progressive disease, 
by day 712 mutant DNA was not detected and the patient 
remains well with stable disease 1,260 days following sur-
gery. This patient experienced a turbulent postoperative 
course requiring additional surgical procedures shortly after 
Figure 2. Comparison of pretreatment ctDNA levels with clinical records. (A) Kaplan–Meier analysis of  patients with GII tumors with either detectable 
or undetectable ctDNA pretreatment, (B) maximum dimension of tumors compared with whether ctDNA could and could not be detected pretreatment. 
(N.D., not detected)
Figure 3. Time course figures for patients with serial analysis of ctDNA. Patient ID and grade are shown in the top left of each figure. Disease status 
is shown at the bottom left of each figure. X- axis: days since primary surgery. Y- axis: mutant IDH1 copies/mL plasma. Red points indicate a negative 
result of 1 or no droplets, blue points indicate ctDNA positive time points. C, chemotherapy; S, surgery, M, metastasis, LR, local recurrence. CS01 and 
CS20 have been excluded from this figure as all time points were negative.
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the primary operation. Patient CS04, who also has Ollier 
disease, had a GI CS and IDH1 mutant molecules detect-
able in plasma postoperatively on three different time 
points. This patient did not have detectable levels before 
surgery and currently has stable disease. The ctDNA levels 
in two patients (CS24 and CS21) with GII disease remained 
detectable in the first postsurgery sample (day 107 and 
day 3, respectively) and then became equivocal. Both these 
patients subsequently developed metastatic disease 
(510 days and 150 day after surgery, respectively). The 
fifth patient (CS08), who had an intralesional excision of 
a dedifferentiated CS was found to have significantly raised 
ctDNA levels when first tested postsurgery at 359 days at 
which time the patient had metastatic disease.
Finally, we analyzed plasma samples from 42 patients 
with a variety of bone and soft tissue tumors harboring 
a characteristic mutation of their disease using a range 
of hotspot digital PCR assays (Table S2). Presurgery mutant 
MYOD1 p.L122R ctDNA was detected in 2/3 patients with 
a spindle cell rhabdomyosarcoma, all of which harbored 
the characteristic recurrent mutation in their tumors. The 
highly recurrent H3F3A p.G34W reported in giant cell 
tumors of bone was detected in ctDNA from 7/24 patients 
with giant cell tumors of bone all of which had previ-
ously been shown to harbor a H3F3A alteration. However, 
the ctDNA levels were typically very low (2 or 3 mutant 
droplets) except in one patient who had suffered a patho-
logical fracture through the tumor. The characteristic 
recurrent mutations in CTNNB1 (p.T41A, p. S45F) detected 
in desmoid- type fibromatosis from five patients was not 
detected in plasma, nor were the recurrent GNAS (p.
R201H, p.R201C) mutations detected in four and six 
patients with fibrous dysplasia and intramuscular myxoma, 
respectively, whose tumors harbored the relevant GNAS 
mutations.
Discussion
We have assessed the ability to detect and quantify cir-
culating mutant IDH1 using a multiplexed digital PCR 
assay against all common IDH1 mutations in 29 patients 
with CS whose tumors were known to harbor an IDH1 
mutation. We report here that there is complete correla-
tion between the detection of presurgery ctDNA and the 
diagnosis of GIII and dedifferentiated CS. There is also 
100% correlation between failure to detect the mutant 
molecules in the circulation of patients with low grade 
CS harboring an IDH1 substitution. The detection of 
mutant IDH1 ctDNA in patients with GII disease was 
much more variable, being present in 8/17 of presurgical 
samples from these patients. The detection of preoperative 
ctDNA in patients with CS GII was associated with poorer 
prognosis (P- value = 0.0448 Log- rank (Mantel- Cox test) 
(Fig. 2A) with 5/8 patients suffering relapse of persistent 
disease. Overall, our findings reflect the reported behavior 
of CS with these grades: patients with GIII and dedif-
ferentiated CS have a uniformly poor prognosis whereas 
patients with low- grade cartilaginous tumors have an 
excellent outcome. In contrast, GII CS has the most 
unpredictable behavior and 5 year survival [1]. Despite 
histological grading being recognized to be subject to 
inter- and intra- observer variability [2], it is currently the 
best indicator of prognosis. It is therefore interesting to 
speculate that detection of preoperative ctDNA could be 
a more accurate and reproducible prognostic indicator 
than assessment of histological grade.
ctDNA has a half life of approximately one hour, hence 
detection of mutant molecules more than a few days 
postsurgery (depending on initial levels) indicates that 
they must have originated from tumor cells that have 
not been successfully removed. This is consistent with 
the evidence in some cancer types that postsurgical detec-
tion of ctDNA is more likely to be associated with disease 
relapse [23, 24]. It is therefore noteworthy that the five 
patients (CS05, CS10, CS13, CS17, and CS20) who were 
disease- free at the end of the study had no detectable 
ctDNA postsurgery (except in CS05 at a single point where 
1.5 mutant molecules per mL of plasma were detected), 
whereas ctDNA was detectable postsurgery in the 4 patients 
(CS08, CS21, CS24, CS27) who either had relapsed and 
had persistent disease, or died of related disease. One 
patient (CS09) had no detectable ctDNA postsurgery but 
later developed a local recurrence, however, this was 6 years 
after the primary surgery and 66 months after the last 
ctDNA test. A second patient (CS12), who also had no 
detectable ctDNA postsurgery died with pulmonary metas-
tases 447 days after the last ctDNA test. Furthermore the 
findings suggest that this assay may be useful for detecting 
residual and metastatic CS earlier/more sensitively than 
imaging, and thereby could allow earlier surgical interven-
tion. From a therapeutic perspective, a number of new 
approaches are being explored including IDH1- targeted 
therapy [25, 26]. Hence, utilization of the assay may not 
only enable improved stratification for recruitment into 
trials but also the monitoring of treatment response.
Ollier disease is brought about by an early postzygotic 
mutation in IDH1 or IDH2 [14]. ctDNA increased post-
surgery in 2/3 Ollier patients (CS04 and CS14). However, 
it is not clear if the IDH1 mutant ctDNA molecules derived 
from tumor or nontumor mosaic tissues. It is conceivable 
that the trauma of surgery resulted in release of molecules 
from non- lesional IDH1 mutant tissue, a suggestion sup-
ported by the reduction to undetectable levels in one patient 
who was followed for 37 months, and the finding that 
IDH1 molecules were detected postsurgery in the patient 
CS04 with GI Ollier disease when it was not detected prior 
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to treatment. Monitoring ctDNA levels in multiple patients 
with Ollier disease over a longer period and correlation 
with clinical progression is required to establish the value 
of this test in detection of disease progression.
Our finding that mutant IDH1 ctDNA was detected in 
the vast majority of patients with high grade CS harbor-
ing an IDH1 mutation indicates that preoperative detection 
of ctDNA could potentially replace the need for a CT- 
guided needle biopsy—the conventional means of obtaining 
a bone tumor diagnosis. However, introducing such a 
change in practice could only be pursued if imaging, a 
vital component of the diagnostic process, correlated with 
ctDNA levels, and the results were confirmed in a larger 
cohort. The failure to detect ctDNA even if the imaging 
supported a diagnosis of cartilaginous tumor could be 
explained on the basis that ctDNA levels are not expected 
to be detected in GI CS and some GII CS harboring the 
mutation, in addition to which only 55% of conventional 
central CS harbor an IDH1 mutation.
On extending our analysis to other bone and soft tissue 
tumors we have shown that there is a clear trend for 
higher levels of ctDNA in patients with higher- grade dis-
ease. Specifically ctDNA was detected in 2/3 patients with 
spindle cell rhabdomyosarcoma, whereas only small num-
bers (2 or 3) of mutant molecules were detected in ~30% 
of patients with GCT of bone, a locally aggressive bone 
tumor. The patient with GCT of bone who had a high 
mutant burden had suffered a pathological fracture. 
Furthermore, mutant molecules were not detected in 
plasma of patients with desmoid- type fibromatosis, fibrous 
dysplasia and intramuscular myxoma, all of which are 
slow- growing indolent neoplasms which do not metastasize 
and in which necrosis is not found.
A limitation of this study is that IDH1 mutants are only 
detected in approximately 50% of CS. Through exome 
sequencing of these tumors we have shown that a number 
of other mutations occur recurrently in a relatively small 
number of genes in the presence and absence of the IDH 
substitutions. These include COL2A1 aberrations in 37% 
of cases, TP53 mutations in 20% and mutations in the 
RB1 pathway (primarily CDKN2A deletion) and hedgehog 
signaling pathway at 33% and 18%, respectively [27]. 
However, these genetic alterations involve numerous loci 
in the genes and therefore require the development of more 
complex assays. Although being pursued, optimization of 
such assays are best undertaken in cancers more common 
than CS [7, 8]. A second limitation of the study is the 
variable amount of plasma DNA collected (0.2–6.3 mL) 
and the inconsistent time points at which this collection 
occurred. Future project design should include a minimum 
of 5 mL of plasma collected at predetermined occasions.
The results from this pilot study involving rare connective 
tissue tumors with highly recurrent hotspot mutations 
provide evidence that ctDNA may have useful applications 
including a more accurate prognostic indicator than is cur-
rently available, and the ability to detect residual disease/
relapse postsurgery. In the latter scenario, utilisation of blood 
preservation tubes such as Streck or PAXgene Blood ccfDNA 
tubes would permit a delay in blood processing without 
causing a notable increase in the fraction of nontumor 
genomic DNA from lysed white blood cells [28]. This 
enhances the potential for closer monitoring of patients, as 
blood can be drawn at their general practitioner’s and sent 
to a central laboratory for processing and analysis. The 
findings argue generally for systematic collection of ctDNA 
from patients, particularly with rare diseases, as this will 
allow accelerated optimization of assays and the value of 
this technology to be assessed. The IDH1 ctDNA data in 
patients with CS presented in this study argue for a large 
multicentre prospective study to confirm our findings.
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Additional supporting information may be found in the 
online version of this article:
Table S1. Full CS patient data.
Table S2. All non- CS patient results.
Table S3. IDH1 multiplex assay details.
Table S4. GNAS multiplex assay details.
Table S5. SinglePlex assay details.
Table S6. Cycling conditions.
Table S7. No template control results.
Data S1. Methods.
Figure S1. An example of a rejected assay in which 
the reaction amplification failed.
Figure S2. IDH1 R132 multiple assay testing in posi-
tive and negative control material. Droplets containing 
1 or more mutant molecules are blue, droplets with 
one or more wild type molecules are green and the 
red droplets contain one or more of each. Empty drop-
lets are grey. As demonstrated through analysis of tumor 
DNA with known mutations the assay is able to cor-
rectly detect each of the five mutations with very low 
background in wild type DNA. (A) p.R132G, (B) 
p.R132H, (C) p.R132L, (D) p.R132S, (E) p.R132C, (F) 
wild type. The wild type figure is a composite of 5 
runs. This was needed to detect the extremely low 
background level.
